SCHEMBL16416752

SCHEMBL16416752

Fc1ncccc1OCc1ccccc1

nearest known ligand 0.64

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LTA4H P09960 1/20 0.64
MAPK14 Q16539 1/20 0.64
MEN1 O00255 2/20 0.53
KMT2A Q03164 2/20 0.53
NPC1 O15118 2/20 0.53
RAB9A P51151 2/20 0.53
MAPT P10636 1/20 0.52
MAPK1 P28482 1/20 0.52
TDP1 Q9NUW8 1/20 0.52
L3MBTL1 Q9Y468 1/20 0.52
PPIA P62937 2/20 0.49
ABCB1 P08183 1/20 0.49
HTR1A P08908 2/20 0.49
DRD2 P14416 2/20 0.49
SGMS2 Q8NHU3 2/20 0.48
PDE5A O76074 1/20 0.48
PDE4A P27815 1/20 0.48
PDE4B Q07343 1/20 0.48
PDE4C Q08493 1/20 0.48
PDE4D Q08499 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8526782 0.79 LTA4H (0.66) LTA4HMAPK14MEN1KMT2ANPC1
SCHEMBL14514408 0.79 LTA4H (0.60) LTA4HMAPK14MEN1KMT2ANPC1
SCHEMBL31121576 0.78 LTA4H (0.64) LTA4HMAPK14MEN1KMT2ANPC1
SCHEMBL105010 0.78 LTA4H (1.00) LTA4HMAPK14NPC1RAB9AMAPT
SCHEMBL30711987 0.78 LTA4H (0.64) LTA4HMAPK14MEN1KMT2ANPC1
SCHEMBL7464316 0.78 BRD4 (0.59) LTA4HMAPK14KMT2AMAPTMAPK1
SCHEMBL8825232 0.78 LTA4H (0.64) LTA4HMAPK14MEN1KMT2ANPC1
SCHEMBL1563544 0.78 LTA4H (0.64) LTA4HMAPK14NPC1RAB9AMAPT
SCHEMBL2339072 0.78 LTA4H (0.64) LTA4HMAPK14MEN1KMT2ANPC1
SCHEMBL1805748 0.78 LTA4H (0.64) LTA4HMAPK14MEN1KMT2ANPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-114945571-B Cyclic compounds and methods of use thereof 薛定谔公司 2025-02-25 CN disclosed
US-20240018157-A1 CYCLIC COMPOUNDS AND METHODS OF USING SAME SCHRÖDINGER, INC. 2024-01-18 US disclosed
US-20240018157-A1 CYCLIC COMPOUNDS AND METHODS OF USING SAME SCHRÖDINGER, INC. 2024-01-18 US disclosed
US-20240018157-A1 CYCLIC COMPOUNDS AND METHODS OF USING SAME SCHRÖDINGER, INC. 2024-01-18 US disclosed
EP-4081526-A1 CYCLIC COMPOUNDS AND METHODS OF USING SAME Schrödinger, Inc. (US) 2022-11-02 EP disclosed
CN-114945571-A Cyclic compounds and methods of use thereof 薛定谔公司 2022-08-26 CN disclosed
WO-2021134004-A1 CYCLIC COMPOUNDS AND METHODS OF USING SAME SCHRODINGER, INC. (US) 2021-07-01 WO disclosed
WO-2021134004-A1 CYCLIC COMPOUNDS AND METHODS OF USING SAME SCHRODINGER, INC. (US) 2021-07-01 WO disclosed
US-9701635-B2 C-H fluorination of heterocycles with silver (II) fluoride THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2017-07-11 US disclosed
US-20160185723-A1 C-H FLUORINATION OF HETEROCYCLES WITH SILVER (II) FLUORIDE NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2016-06-30 US disclosed
WO-2015013715-A2 C-H FLUORINATION OF HETEROCYCLES WITH SILVER (II) FLUORIDE THR REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2015-01-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160185723-A1 C-H FLUORINATION OF HETEROCYCLES WITH SILVER (II) FLUORIDE AFF2, INF2, NPFFR2 LTA4H 2687/4885MAPK14 4570/4885MEN1 941/4885
US-20240018157-A1 CYCLIC COMPOUNDS AND METHODS OF USING SAME MALT1, FKBP1B, FKBP1A LTA4H 1783/4885MAPK14 1757/4885MEN1 82/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.